Life Sciences

  • April 28, 2026

    Eli Lilly Inks $2.25B AI Genetics Research Pact With Profluent

    AI-focused biotech Profluent said Tuesday it has entered a multiprogram, strategic research collaboration with Eli Lilly and Co. to treat diseases with high unmet need, in a deal that involves an upfront payment and up to $2.25 billion in additional milestone payments. 

  • April 28, 2026

    Meet The Attys Arguing The High Court 'Skinny Label' Case

    When the U.S. Supreme Court hears arguments Wednesday in a patent case involving "skinny labels" on generic drugs, a longtime patent attorney as well as a government attorney who often handles intellectual property cases will face an appellate specialist who has argued many high court cases.

  • April 27, 2026

    North Dakota Drug-Pricing Law Blocked In Pharma Fight

    A North Dakota federal judge on Monday blocked the state's new drug-pricing law, agreeing with pharmaceutical companies that while the law purports to "protect the underdogs," it illegally interferes with the federal drug-pricing regime.

  • April 27, 2026

    Did Hedge Fund 'Greed' Hurt Vaxart Investors? Jury To Decide

    Armistice Capital and two of its executives used misleading press releases to pump and dump $250 million in Vaxart stock during the pandemic through misleading press releases in an act of pandemic-era "greed," investors' counsel told a California federal jury during closing arguments Monday, while the hedge fund defendants' lawyer countered Vaxart's announcements were "true and accurate."

  • April 27, 2026

    DOJ Says Wash. 340B Drug Law Is Preempted In Novartis Suit

    The U.S. Department of Justice waded into a dispute between pharmaceutical giants and the state of Washington on Monday, arguing that federal law preempts a new state law that expands discounts that drugmakers must provide under the federal 340B Drug Pricing Program.

  • April 27, 2026

    High Court Appears Split In Monsanto Roundup Appeal

    Monsanto's efforts to stem the tide of thousands of lawsuits over its blockbuster weedkiller Roundup seemed to find a mixed audience with the U.S. Supreme Court justices Monday as they debated the benefits of national labeling standards with how regulators stay on top of changing science.

  • April 27, 2026

    Moderna Hit With Suit Over CureVac COVID Patents

    BioNTech subsidiary CureVac has launched a new patent infringement suit against Moderna, claiming its COVID-19 vaccine infringed a handful of patents, saying the Massachusetts-based company "exploited" its messenger RNA technology.

  • April 27, 2026

    Attys, Advocates Call DOJ Pot Rule Historic Shift For Feds

    Legal strategies are evolving quickly in the wake of last week's "historic" rescheduling of state-legal medical cannabis, as a group of attorneys and advocates gathered Monday to evaluate the trade-offs of dispensaries now being able to register like pharmacies with the feds and the potential effect on industry investments and trade.

  • April 27, 2026

    IQVIA Accuses Ex-Execs, Syneos Of Poaching $180M Client

    IQVIA Holdings Inc. is accusing former executives of defecting to a competitor in the clinical research organization industry and initiating a corporate raid that resulted in the loss of one customer worth at least $180 million, according to a lawsuit filed in North Carolina Business Court.

  • April 27, 2026

    4 Firms Build Astorg's $1.1B Microbiology Biz Buy

    Life sciences company Thermo Fisher Scientific Inc. on Monday announced plans to sell its microbiology business to European private equity firm Astorg in an over $1.1 billion deal steered by four law firms.

  • April 27, 2026

    3rd Circ. Panel Once Again Backs Talc Co. Whittaker's Ch. 11

    The Third Circuit on Monday upheld its decision that Whittaker Clark & Daniels was authorized to file for Chapter 11 and certain claims against the defunct talc supplier's corporate successor belong to the debtor, not personal injury claimants.

  • April 27, 2026

    Bioscience Co. Allegedly Hid Volatility Risks From Investors

    A company purportedly focused on using traditional Chinese medicine to treat conditions including autism spectrum disorder faces a proposed investor class action alleging it downplayed the risk it would be probed in connection with unusual volatility affecting the market for its shares.

  • April 27, 2026

    McCarter & English Plans New Waterfront Home In Boston

    New Jersey-based McCarter & English LLP has chosen a new home for its Boston office, opting for a location in the middle of the city's downtown waterfront district, the firm has announced.

  • April 27, 2026

    Catching Up With Delaware's Chancery Court

    The Delaware Chancery Court this past week tackled a fresh mix of deal litigation, procedural disputes and fiduciary duty claims, with several rulings and filings underscoring the court's continued focus on contractual precision, forum enforcement and the limits of stockholder challenges.

  • April 27, 2026

    What To Watch As Justices Take On 'Skinny Label' Case

    The U.S. Supreme Court will hear arguments Wednesday on whether to permit a patent suit over a generic heart drug using a so-called skinny label, a case with ramifications for the drug industry that could shape patent disputes more broadly and other legal areas. Here's what to watch for.

  • April 27, 2026

    Ropes & Gray, Cooley Lead Lilly's $2.3B Cancer Drug Buy

    Eli Lilly and Co. said Monday it will acquire privately held Ajax Therapeutics in a deal worth up to $2.3 billion, as the drugmaker looks to expand its pipeline of treatments for blood cancers.

  • April 27, 2026

    US, Indian Firms Guide $11.75B Sun Pharma-Organon Deal

    Indian pharmaceutical giant Sun Pharmaceutical Industries Ltd. has agreed to acquire New Jersey-based Organon & Co. in an all-cash deal valued at $11.75 billion, with each side of the transaction having representation from one U.S. and one Indian law firm.

  • April 24, 2026

    Up Last At High Court: TPS, Geofence, Skinny Labels

    The U.S. Supreme Court will close out its oral argument portion of the 2025 October term by hearing a panoply of disputes over the constitutionality of geofence warrants, the existence of aiding and abetting torture claims, and the rescission of temporary protected status for hundreds of thousands of immigrants.

  • April 24, 2026

    Natera Tells Justices CareDx Made Up Circ. Split In Petition

    Natera asked the U.S. Supreme Court to reject a petition from rival CareDx asking it to review a Third Circuit decision that erased a $45 million jury verdict stemming from CareDx's false advertising claims, saying Friday the circuit split that CareDx claims exists is "imagined."

  • April 24, 2026

    NY Court Pauses $100M Saudi Arabia Pharma Award Suit

    A New York federal judge has paused litigation filed by a Qatari pharmaceutical distributor and its chairman aimed at enforcing a nearly $100 million arbitral award against Saudi Arabia while a hearing is conducted in the kingdom's set-aside petition in England next week.

  • April 24, 2026

    What's At Stake As High Court Hears Roundup Appeal

    With a $7.25 billion deal potentially at stake, Monsanto heads to the U.S. Supreme Court on Monday in its closely watched appeal of a $1.25 million jury verdict awarded to a Missouri man who claimed that Roundup weed killer caused his cancer.

  • April 24, 2026

    Danaher Execs Face Investor Suit Over Post-COVID Outlook

    Danaher Corp. executives are facing a proposed securities class action in Delaware federal court alleging they profited while misleading stockholders about the slowing sales of its diagnostics and bioprocessing products.

  • April 24, 2026

    Merck's $6.7B Terns Deal Clears Regulatory Hurdle

    Merck has cleared a key regulatory hurdle in its plan to acquire clinical stage oncology company Terns Pharmaceuticals Inc. for $6.7 billion, the pharmaceutical giant said Friday. 

  • April 24, 2026

    Pfizer, Dexcel Drop Heart Drug Case Before Bench Trial

    Pfizer and Israeli generic-drug maker Dexcel on Friday agreed to drop a case Pfizer brought to block Dexcel from creating a generic version of the heart medication Vyndamax.

  • April 24, 2026

    Biotechs Clash Over Cancer Drug Discovery In Chancery

    AnaptysBio and Tesaro, alongside Tesaro parent GlaxoSmithKline LLC, sparred Friday in the Delaware Chancery Court over the scope of discovery in the biotechnology firms' contract fight regarding cancer drug Jemperli, with each side accusing the other of trying to tilt the evidentiary record ahead of a fast-approaching trial in July.

Expert Analysis

  • The Benefits Of Choosing A Niche Practice In The AI Age

    Author Photo

    As artificial intelligence becomes increasingly accessible, lawyers with a niche practice may stand out as clients seek specialized judgment that automation cannot replicate, but it is important to choose a niche that is durable, engaging and a good personal fit, says Daniel Borneman at Lowenstein Sandler.

  • How PBMs Can Adapt To Plan Sponsors' Disclosure Demands

    Author Photo

    As federal reforms, growing state regulation and litigation threats push plan sponsors to expect visibility into revenue streams, pharmacy benefit managers should leverage transparency strategically, including by simplifying how they get paid, offering clients audit-ready data and co-designing contracts that are easy for fiduciaries to explain and defend, says Kristie Blase at Frazer + Blase.

  • What New Animal Welfare Enforcement Push Means For Cos.

    Author Photo

    The Trump administration's recently announced multiagency focus on violations of the Animal Welfare Act and related laws will likely lead to broader enforcement actions across industries, heightened scrutiny of compliance standards and a need for businesses to adopt effective risk management practices, says Shennie Patel at Crowell & Moring.

  • How To Engage With Gov't's Direct-To-Consumer Drug Policy

    Author Photo

    The U.S. Department of Health and Human Services' recent request for industry input on manufacturers' direct-to-consumer drug sales reflects the government's caution in this arena, and allows stakeholders a rare opportunity to help shape policy, says Mary Kohler at Kohler Health Law.

  • Series

    Podcasting Makes Me A Better Lawyer

    Author Photo

    Podcasting has changed how I ask questions and connect with people, sharpening my ability to listen without interrupting or prejudging, and bringing me closer to what law is meant to be: a human profession grounded in understanding, judgment and trust, says Donna DiMaggio Berger at Becker.

  • Patent Eligibility Bulletin: Steps To Consider As USPTO Shifts

    Author Photo

    Recent memoranda from the U.S. Patent and Trademark Office, along with some of the first patents issued under Director John Squires, indicate a recalibration of the subject matter eligibility landscape, signaling a renewed emphasis on concrete technological improvements and a potentially pro-AI stance, say attorneys at Banner Witcoff.

  • Tax Court Ruling Signals Cross-Border Loan Scrutiny

    Author Photo

    The U.S. Tax Court’s recent decision in Aventis v. Commissioner compounds ongoing regulatory focus on debt originations and should prompt practitioners to assess their existing cross-border lending structures for potential exposure to U.S. federal income tax, say attorneys at Eversheds.

  • Lessons From Justices' Split On Major Questions Doctrine

    Author Photo

    The justices' varied opinions in Learning Resources v. Trump, which held the International Emergency Economy Powers Act did not confer the power to impose tariffs, offer a meaningful window into the U.S. Supreme Court's perspective on the major questions doctrine that will likely shape lower courts' approach to executive action challenges, say attorneys at Venable.

  • Drug Wholesaler's DPA Shows Imperfect Efforts Still Count

    Author Photo

    Atlantic Biologicals’ recent deferred prosecution agreement with federal prosecutors for allegedly distributing controlled substances to pill mill pharmacies demonstrates that even subpar cooperation, when combined with genuine remediation and strategic advocacy, can yield outcomes that protect a company's long-term interests, says Jonathan Porter at Husch Blackwell.

  • Key Takeaways As HRSA Aims To Revive 340B Rebate Pilot

    Author Photo

    The U.S. Department of Health and Human Services' recent request for feedback on the 340B Rebate Model Pilot Program demonstrates that it intends to correct the model's procedural defects, which is positive news for participating manufacturers, but a setback for covered entities, say attorneys at Manatt.

  • When MDLs Drag, State Courts Can Speed Mass Tort Results

    Author Photo

    Understanding the structural dynamics that can delay resolution in multidistrict litigation is essential to understanding why a state court strategy is sometimes not merely attractive, but necessary for plaintiffs seeking timely and just outcomes, say attorneys at DiCello Levitt.

  • Leveraging MDLs And State Courts In Mass Tort Strategy

    Author Photo

    Multidistrict litigation's quiet drift from a pretrial coordination device to a de facto national court for mass torts poses a strategic question for plaintiffs counsel — whether an MDL will yield timely trials, meaningful accountability and fair value for clients, or whether a state court strategy will be more effective, say attorneys at DiCello Levitt.

  • Unique Issues Facing Brand-Compounder Patent Litigation

    Author Photo

    Recent litigation and potential enforcement action against Hims & Hers Health raise questions about how compounders and branded pharmaceuticals companies would be positioned in patent litigation as compared to generics companies, which would require strategies different from those that would be used in traditional Hatch-Waxman Act litigation, say attorneys at Morgan Lewis.

  • Series

    Volunteering With Scouts Makes Me A Better Lawyer

    Author Photo

    Serving as an assistant scoutmaster for my son’s troop reaffirmed several skills and principles crucial to lawyering — from the importance of disconnecting to the value of morality, says Michael Warren at McManis Faulkner.

  • Series

    Law School's Missed Lessons: In Court, It's About Storytelling

    Author Photo

    Law school provides doctrine, cases and hypotheticals, but when lawyers step into the courtroom, they must learn the importance of clarity, credibility, memorability and preparation — in other words, how to tell simple, effective stories, say Nicholas Steverson and Danielle Trujillo at Wheeler Trigg, and Lisa DeCaro at Courtroom Performance.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.